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ABSTRACT
Introduction: Irrational use of antibiotics is a serious
issue within China and internationally. In 2012, the
Chinese Ministry of Health issued a regulation for
antibiotic prescriptions limiting them to <20% of all
prescriptions for outpatients, but no operational details
have been issued regarding policy implementation. This
study aims to test the effectiveness of a
multidimensional intervention designed to reduce the
use of antibiotics among children (aged 2–14 years old)
with acute upper respiratory infections in rural primary
care settings in China, through changing doctors’
prescribing behaviours and educating parents/caregivers.
Methods and analysis: This is a pragmatic, parallel-
group, controlled, cluster-randomised superiority trial,
with blinded evaluation of outcomes and data analysis,
and un-blinded treatment. From two counties in Guangxi
Province, 12 township hospitals will be randomised to
the intervention arm and 13 to the control arm. In the
control arm, the management of antibiotics prescriptions
will continue through usual care via clinical
consultations. In the intervention arm, a provider and
patient/caregiver focused intervention will be embedded
within routine primary care practice. The provider
intervention includes operational guidelines, systematic
training, peer review of antibiotic prescribing and
provision of health education to patient caregivers. We
will also provide printed educational materials and
educational videos to patients’ caregivers. The primary
outcome is the proportion of all prescriptions issued by
providers for upper respiratory infections in children
aged 2–14 years old, which include at least one
antibiotic.
Ethics and dissemination: The trial has received
ethical approval from the Ethics Committee of Guangxi
Provincial Centre for Disease Control and Prevention,
China. The results will be disseminated through
workshops, policy briefs, peer-reviewed publications,
local and international conferences.
Trial registration number: ISRCTN14340536;
Pre-results.
INTRODUCTION
Irrational use of antibiotics is a serious issue
within China and internationally. Worldwide,
around 50% of medicines are not appropri-
ately prescribed, dispensed or sold.1–3
Irrational use of antibiotics not only brings
high economic burdens to health systems,
but also increases the risk of antibiotic resist-
ance.1 Acute upper respiratory infections
(URIs) are very common among children;
however, most are usually viral and self-
limiting, with antibiotic treatment for URIs
being unnecessary. For example, a systematic
review has shown that antibiotic use does not
shorten the duration of URIs.4 Despite this,
there is a high prevalence of antibiotics pre-
scriptions for URIs in primary care facilities.5
Antibiotic resistant bacteria are also fre-
quently found in children, especially in
infants and particularly in countries with less
Strengths and limitations of this study
▪ We aim to test a comprehensive intervention
targeting doctors and patients/caregivers, an
approach shown to have the largest effect on
reducing the irrational prescribing of antibiotics
in rural primary care settings.
▪ The study is adapted to the local context and fits
into the current Chinese national priority on
antibiotics control.
▪ All the interventions are embedded within routine
primary care management and practice, thus
enhancing the potential scale-up of the
intervention.
▪ The effectiveness of the pragmatic trial may be
limited by various contextual factors; and this
will be explored by a qualitative process
evaluation.
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stringent prescribing regulations in healthcare and
agriculture.6
Overuse of antibiotics in healthcare is common in
China. In 2012, the national Ministry of Health reported
that the average person consumed 138 g of antibiotics
per year, 10 times the rate in USA.7 The situation is
worst in rural areas where health workers receive less
education and continuous medical training in practice.8
Knowledge and awareness about antibiotic misuse and
resistance is also poorer in rural communities compared
to urban residents.9 Another recent study found fre-
quent and inappropriate use of antibiotics in primary
healthcare settings in China, 78% antibiotics were pre-
scribed for colds and 93.5% for acute bronchitis.10 An
earlier study in the primary care settings of 10 provinces
in rural Western China showed that antibiotics
accounted for nearly half of all prescriptions predomin-
antly provided for URIs, while one-fourth of those
receiving antibiotics were children under 10 years old.11
Several national policies have been issued by the
Ministry of Health, including the most recent policy lim-
iting antibiotic prescriptions to <60% of all prescriptions
for inpatients and 20% for outpatients.12 However, no
operational details were provided on how to implement
the policy, and no guidelines were provided on the diag-
nosis and treatment of childhood URIs or the related
clinician training, especially for primary care doctors. In
the 2009 health sector reforms, China launched the
Essential Medicines List policy which was supported by
the centralised procurement of essential medicines and
the Zero-Markup policy. However, even after 2 years of
implementation there was no signiﬁcant improvement in
the rational use of medicines and cost control.13
The majority of studies on reducing irrational anti-
biotic use have been conducted in developed countries,
and these have demonstrated that improving knowledge,
attitudes and behaviours of healthcare providers and
consumers can effectively reduce irrational antibiotic
use.14 Commonly reported interventions for improving
antibiotic use in URI treatment included clinical deci-
sion support,15–19 point-of-care testing for C-reactive
protein,20–23 clinician communication skills training,20–22
education and feedbacks,24 discussion and monitoring
workshops,25 governance structure change26 and behav-
ioural economics and social psychology.27 A Cochrane
review demonstrated that multifaceted interventions tar-
geting both physicians and patients signiﬁcantly reduced
inappropriate antibiotic use in community settings;28
whereas single interventions with parents failed to
impact on antibiotic prescribing.29–31
Studies of irrational antibiotic prescribing in primary
care settings in China are currently limited, and mainly
cross-sectional surveys.10 11 Studies involving interven-
tions aimed at reducing the irrational prescribing of
antibiotics in primary care are rare, except one study
showing limited impact of a public reporting interven-
tion for reducing antibiotics prescribing in primary care
facilities.32 Therefore, we aim to test the effectiveness of
a multidimensional intervention targeting doctors’ pre-
scribing behaviours and the education of parents/care-
givers which we hypothesise will reduce the irrational
use of antibiotics among children with acute URIs in
China’s rural primary care context.
METHODS AND ANALYSIS
Design of the study
This is a parallel-group, cluster randomised controlled
trial designed as a pragmatic evaluation of the superior-
ity of a health behaviour change intervention compared
with routine practice (ﬁgure 1). The study will be con-
ducted in 25 township hospitals, with randomisation
stratiﬁed by county. Randomisation is at the level of
township hospitals because it would not be practical or
logistically feasible to randomise individual doctors or
patients/caregivers in this multidimensional interven-
tion that involves both provider and patient/caregivers
components. Study participants and doctors will not be
blinded to the treatment, but measures will be taken to
ensure a blinded outcome evaluation by using the
‘PROBE’ design.33
The study design broadly follows the Medical Research
Council framework ‘Developing and evaluating complex
interventions: new guidance’.34 Prior to the conduct of
the trial, we conducted a systematic review of interven-
tions aimed at reducing antibiotic use in children with
URIs.35 We then developed our intervention based on
the results, which supported ﬁndings28 that interven-
tions targeting both clinicians and patients had a greater
effect on reducing irrational antibiotic use than those
targeting a single group. An internal pilot approach will
be used to examine the feasibility and acceptability of
the intervention, and the research procedures in six
township hospitals. An independent trial steering com-
mittee, where lead investigators will be steering commit-
tee members, has also been set up to supervise the trial,
review progress and if necessary, decide on any changes
to the protocol. A data monitoring committee will not
be set up given the lack of any interim analyses and very
low risk to participants, but the statistician will provide
any data advice to the trial steering committee, as
necessary.
Setting
The trial will take place in two counties of Guangxi prov-
ince, which is one of the poorest provinces in China,
and is located in the southwest mountainous terrain
joining Vietnam and Laos. Guangxi has a population of
48 million and contains 110 counties. In the rural areas,
primary care is provided by public township hospitals
and this trial will be conducted in 25 such hospitals.
Each township hospital covers 20 000 to 100 000 people,
and doctors in the township hospitals are responsible
for acute and preventive care. Although township hospi-
tals have inpatient treatment facilities, we only consider
outpatients in this study because inpatients are likely to
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have a range of comorbidities, leading to difﬁculty in
assessing rational prescribing for URIs. Each township
hospital has 5–20 doctors. No booking system is oper-
ational in rural township hospitals. We have not included
village clinics, often equipped with an upgraded commu-
nity health worker, the ‘village doctor’, because both
public and private clinics co-exist, which may confound
the interventions. Rather, our intervention focuses on
professionally qualiﬁed public clinicians who work as
general practitioners (‘doctors’) in township hospitals.
Eligibility
Eligibility criteria for clusters
All doctors working in township hospitals from the two
selected counties in Guangxi who agreed to participate
in the study are included. We excluded the two township
hospitals located in the two county centres, as these have
much better staff capacity and equipment than their
peers and are close to the county general hospital. Both
counties have implemented the Essential Medicine List,
its treatment guidelines, and the Zero-Markup Policy
since 2012.
Eligibility criteria for participants
All outpatient prescriptions for children aged between 2
and 14 years, and diagnosed with URIs during the base-
line and intervention data collection period (ﬁgure 1)
will be included for analysis. Children under 2 years will
be excluded as they are more vulnerable to secondary
bacterial infection, and exploratory work indicated that
it was very difﬁcult for doctor’s to refuse antibiotics for
younger children in this context. Prescriptions for
Figure 1 Trial flow chart.
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children diagnosed with pneumonia (where antibiotic
prescription is appropriate) or severe diseases
(eg, cancer, tuberculosis, HIV/AIDS/immunodeﬁciency,
chronic heart diseases) or others who need long-term
antibiotic treatment or prophylaxis will be excluded.
Intervention
No antibiotic should be used for self-limiting viral URIs
as per the national and international guidelines. The
multidimensional intervention is aimed at changing
doctors’ prescribing behaviours and educating parents/
caregivers to reduce the irrational use of antibiotics
among children with acute URIs. It is designed to ﬁt
within the policy requirements of antibiotics prescribing
and routine supervision by the local health authorities.
The intervention design is informed by the
Theoretical Domains Framework (TDF), an emerging
method developed from a wide range of theories
relevant to behavioural change. The TDF, which consists
of 14 theoretical domains (groups of constructs from
theories of behaviour change) has been widely used for
exploring inﬂuencing factors and designing of interven-
tions36 37 38 in implementation research. Based on our
exploratory study and systematic review, several theoreti-
cal domains from the TDF were identiﬁed as important
in antibiotic prescribing, in which relevant behaviour
change techniques and content of interventions were
targeted (table 1).39
For the doctors the intervention includes: (1) oper-
ational guidelines to be distributed among township hos-
pital doctors. The guidelines are based on Chinese
antibiotics use guidelines, Integrated Management of
Childhood Illness (IMCI) guidelines and the National
Institute for Health and Care Excellence UK (NICE)
guidelines; these focus on but are not limited to URIs.
The operational guidelines cover the workﬂow of URI
Table 1 Multidimensional interventions designed to reduce the use of antibiotics among children
Targeted group Theoretical domains Behaviour change techniques, modes and content of delivery
Provider side
(doctors)
1. Knowledge
2. Skills
3. Beliefs about capabilities
Techniques: information provision.
Mode 1: operational guidelines.
Content: URI management work flow, methods of diagnosis of URI and
other common diseases among children, communication skills between
clinicians and patients.
Mode 2: facilitated training/workshop.
Content: rational antibiotics use especially for childhood URI (using
lectures, case discussions and Q&A (participatory and interactive)).
Behaviour regulation Techniques: monitoring and feedback.
Mode: antibiotics prescribing appraisal.
Contents/procedures:
(1) Monthly antibiotic prescriptions collected by research team at the
beginning of every month; (2) Feedback sent back to township hospital
after calculating the APR by research team; (3) Antibiotics use
appraisal according to APR feedback in monthly hospital staff meeting;
(4) Meeting memo written down by the township coordinator; (5)
Township coordinator sends the memo to trial manager.
1. Beliefs about
consequences
(caregivers)
2. Knowledge (caregivers)
3. Social influence
(caregivers)
Techniques: information provision and persuasive communication.
Mode: health education to patient caregivers during clinical
consultations.
Content: specific short messages, eg., definition of antibiotic, rational
antibiotic use for childhood URIs, plus simple printed educational
materials.
Consumer side
(parents/caregivers)
1. Beliefs about
consequences
(caregivers)
2. Knowledge (caregivers)
3. Social influence
(caregivers)
Techniques: information provision.
Mode 1: Educational messages from doctors, and educational material/
leaflets.
Content: explanation about antibiotics, the impacts of antibiotic
resistance and rational antibiotics use for childhood URIs (using leaflets
with simple words and pictures).
Mode 2: educational videos played at township hospitals (5–8 min).
Content: explanation about antibiotics, the situation of irrational use of
antibiotics in China, and the impact of antibiotic resistance (using a
local TV show).
Eligible participants include all outpatient prescriptions for children, aged between 2 and 14 years, diagnosed with URIs.
Intervention package for doctors includes: operational guidelines, training, peer-review meetings, consultation (with educational leaflets); and
for parents/caregivers includes: messages from doctors, educational leaflets and videos.
Usual care refers to healthcare as per routine practice at discretion of individual doctors.
Baseline data: 3 months before intervention; outcome data: the past 3 months of the intervention.
URIs, upper respiratory infections.
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management, methods of diagnosis of URIs and other
common diseases among children, and communication
skills between doctors and patients; (2) training work-
shops in which all the doctors in township hospitals will
be trained on the rational use of antibiotics, especially
for childhood URIs, through participatory and inter-
active lectures, case discussions, and question and
answer sessions. These two components address the the-
oretical domains of knowledge, skills and beliefs about
capabilities of rational prescribing, using the technique
of information provision; (3) a monthly peer review of
rational use of antibiotics where antibiotics prescriptions
are collected and reviewed by the research team at the
beginning of each month. The research team calculates
the antibiotic prescription rate (APR) for childhood
URIs and gives the feedback to the township hospitals.
Peer review of antibiotics use are then conducted based
on the APR feedback in the monthly hospital staff
meeting. The project coordinator in the township hospi-
tals will communicate the results of the peer review back
to the research team. This component addresses the the-
oretical domain of behaviour regulation among doctors
by using the techniques of monitoring and feedback;
and (4) health education to caregivers where concise
messages are given by doctors to the caregivers whose
children have URIs during the clinical consultations,
along with simple printed educational materials that
include explanations about antibiotics and rational use
of antibiotics for childhood URIs. This component
addresses the theoretical domains of beliefs about conse-
quences (speciﬁcally of not being given antibiotics),
knowledge and social inﬂuence of antibiotics use among
caregivers/parents, and uses the techniques of informa-
tion giving and persuasive communication.
On the caregivers’ side, the intervention includes: (1)
health education messages from the doctor and printed
educational materials/leaﬂets (with simple words and
pictures) for distribution among caregivers whose chil-
dren have URIs during the clinical consultation. These
mainly cover explanations about antibiotics, the impacts
of antibiotic resistance and rational use of antibiotics for
childhood URIs; and (2) educational videos that are
played on a loop in the waiting areas of township hospi-
tals (5–8 min). The content mainly includes explana-
tions about antibiotics, the situation of irrational use of
antibiotics in China, and the impacts of antibiotic resist-
ance (using a local TV show). This component also
addresses the theoretical domains of beliefs about conse-
quences (speciﬁcally of not being given antibiotics),
knowledge and social inﬂuence of antibiotics use among
caregivers/parents and uses the technique of informa-
tion giving.
Usual care
In the control arm, doctors will be allowed to continue
prescribing antibiotics according to current national
guidelines and existing practices. In these conventional
clinical consultations treatment is provided according to
existing knowledge; antibiotics are given at the individ-
ual clinician’s discretion, and no systematic health edu-
cation is provided to patients. This is, therefore, a
pragmatic comparator reﬂecting typical routine practice,
which allows for useful comparison of the intervention
to the existing situation.
Outcomes
The primary outcome is the APR for childhood URIs,
and will be measured for each township hospital based
on all prescriptions for URIs in outpatients aged
between 2 and 14 years that were issued between the
start of the intervention’s implementation and 6-month
follow-up. Based on these prescriptions, the APR is
deﬁned as the proportion of outpatients aged between 2
and 14 years who have been diagnosed with a URI and
after clinical consultation, prescribed at least one anti-
biotic as a result of the diagnosis. This primary outcome
is selected because it should reﬂect the integrated effect
of the behavioural change in both doctors and patients/
caregivers. A reduction in the APR will be a clinically
beneﬁcial outcome demonstrating increased rational
prescribing of antibiotics, as most self-limiting URIs are
caused by viral infection that do not require antibiotics.
This measurement is reliable and feasible in the primary
care setting where prescriptions are well preserved
either electronically or in paper ﬁles.
The secondary outcomes are all based on data
extracted from the same prescriptions as described for
the primary outcome:
1. The multiple antibiotic prescription rate: the propor-
tion of prescriptions for childhood URIs that include
two or more antibiotics.
2. The broad-spectrum antibiotic prescription rate: the
proportion of prescriptions for childhood URIs that
include at least one broad-spectrum antibiotic.
3. The quinolones prescription rate: the proportion of
prescriptions for childhood URIs that include at least
one quinolone.
4. The mean cost of childhood URI prescriptions.
These secondary outcomes relate to other commonly
observed practices in routine primary care that cause
great concern for their potential to promote
drug-resistance, while misuse of quinolones may also
contribute to the increasing identiﬁcation of extensively
drug-resistant tuberculosis.40
Sample size
Based on our exploratory study, the current APR is
∼50% and this is, therefore, assumed for the usual care
arm. Based on a conservative estimate from our system-
atic review, we expect our intervention to lead to at least
a 25% relative reduction in the antibiotic prescription
rate within township hospitals.35 Consequently, to detect
a 25% or greater reduction in the APR (ie, an absolute
reduction to 37.5% APR or less) with 90% power, by
using two-sided testing at the 5% signiﬁcant level, assum-
ing a harmonic mean cluster size of 200 and a between
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cluster coefﬁcient of variation of 0.15 (based on explora-
tory and pilot work), we estimate that we require 9 town-
ship hospitals per arm.41 Allowing for stratiﬁed
randomisation and a 10% loss of data, due to lost and
illegible prescriptions, this requires a total of 24 town-
ship hospitals. As there are 25 eligible township hospitals
within the two counties, it was decided to include all 25.
Randomisation
A total of 25 township hospitals were eligible for the
trial, with 14 in Rong County and 11 in Liujiang County.
Randomisation was stratiﬁed by county to avoid any
imbalances in allocation between counties, given the
potentially important variation in outcomes between
counties. Within each county, randomisation was further
restricted to two subsets of all possible allocation ratios.
In Rong County, randomisation was restricted to those
allocations resulting in equal numbers of township hos-
pitals in each arm; in Liujiang County, the randomisa-
tion was restricted to those allocations resulting in
township hospital treatment: control arm allocation ratio
of 5:6. This was chosen to ensure as equal an allocation
ratio as possible, while minimising the logistical cost
from treatment arm hospitals. After all 25 hospitals were
randomised, within Rong County, 6 hospitals (3 from
each arm) were further randomly selected to become
the internal pilot clusters. The remaining 19 township
hospitals (8 in Rong County and 11 in Liujiang County)
will, therefore, participate in the main trial, along with
the 6 hospitals involved in the internal pilot. Therefore,
overall the 25 hospitals were allocated in a treatment:
control allocation ratio of 12:13. Randomisation was con-
ducted by the study statistician ( JPH) using a computer
program written in R (V.3.2.0) (Team. RDC. R: A
Language and Environment for Statistical Computing.
Available online at http://www.R-project.org/: Vienna,
Austria: the R Foundation for Statistical Computing,
2011).41
Internal pilot process
The internal pilot study aims to assess recruitment rates
and the extent to which the intervention is delivered
within township hospitals; it will also contribute
outcome data to the main trial. The six township hospi-
tals in the pilot study will be recruited and followed-up
for 3 months, and the decision as to whether to con-
tinue with the full trial will then be taken based on two
key criteria: (1) sufﬁcient levels of recruitment (number
of prescriptions sufﬁcient to achieve minimum sample
size required); (2) feasibility of implementing the inter-
vention (at least 50% of clinicians trained and 50%
using the guidelines at the end of the 3 months after
the intervention). If these criteria are met, the internal
pilot hospitals and their outcome data will then become
part of the main trial, and will be followed up for a
further 3 months. The remaining 19 hospitals will have
been recruited and if the trial is proven to be feasible
via the pilot, these hospitals will be enrolled into the
study and followed-up for 6 months (in other words,
data collection in the pilot and main trial hospitals will
ﬁnish at different times).
Data collection and management
To evaluate the primary and secondary outcomes, 200
prescriptions for childhood URIs will be randomly
selected in each township hospital during the 3 months
before the implementation of the intervention to
provide baseline data, and during the fourth to the sixth
month after randomisation. Prescription data will be
obtained from electronic records where available, or
alternatively photographic copies will be taken of
patients’ paper prescriptions. Data collected from elec-
tronic or photographic records will then be entered into
a password-protected SPSS database (V.20.0, IBM Corp
Armonk, New York, USA). Information collected will
include the township hospital, the date of the prescrip-
tion, the patient’s age, symptoms, diagnosis, prescribed
medicines, related treatment, related laboratory tests,
treatment payment, and insurance status.
Data analysis
Analysis of outcomes
The statistical analyses are described in full detail in the
accompanying statistical analysis plan (see online
Supplementary info 1) and are, therefore, only outlined
in brief here. No interim analyses are planned, and all
outcomes will be analysed following data collection. All
analyses will be on the intention-to-treat (ITT) popula-
tion, deﬁned as all outpatient-prescriptions issued in
township hospitals for URIs in children aged 2–14 years,
regardless of the compliance of township hospitals,
doctors and parents/caregivers to the intervention.
Descriptive statistics will be calculated and presented,
and formal inference will be based on hypothesis testing
with statistical signiﬁcance assessed at the 5% level.
The crude effect of the intervention on outcomes will
be analysed using methods appropriate for cRCTs where
there are small numbers of clusters per arm.41 For the
primary and secondary outcomes involving proportions,
data at the township hospital level will be used to calculate
weighted risk ratios and their 95% CIs (accounting for
between-hospital variance and stratiﬁcation), and formal
hypothesis testing with stratiﬁed t-tests will be conducted.
If the data are strongly skewed, a logarithmic transform-
ation will ﬁrst be applied. The same methods will be used
to analyse the data on the average cost of childhood URI
prescriptions, but based on the weighted mean difference
in the outcome between treatment arms.
To adjust for important covariates, including individual
and contextual factors, a two-stage process will be carried
out.41 This will involve ﬁtting either logistic or normal
regression models (for the proportion or average cost of
prescription outcomes, respectively) to individual-level
outcome data with all covariates of interest (including
stratum) included, apart from the treatment effect.
Township-hospital speciﬁc covariate-adjusted ratio or
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difference residuals will then be calculated for propor-
tion or average cost of prescription outcomes, respect-
ively. Using the methods described above, the
hospital-speciﬁc residuals will then be used in place of
raw hospital-level outcome data to calculate
covariate-adjusted weighted risk ratios/the weighted
mean difference (as appropriate) and their 95% CIs, and
to conduct stratiﬁed t-tests. All data will be analysed using
STATA V.12.1 (SE) (STATA Corporation, College Station,
Texas, USA).
Subgroup analyses
Planned subgroup analyses will be conducted on out-
comes to determine whether there is any signiﬁcant het-
erogeneity in treatment effects occurring between
important groups such as across patients of different
genders and ages, and between hospitals of different
sizes. For each outcome, the cluster-level residuals
described above will be regressed on stratum, treatment
group, the subgroup variable and all their possible
two-way interactions. F-tests will be used to determine
whether there are any signiﬁcant interactions between
treatment group and subgroups.
Process evaluation
A qualitative process evaluation41 will be conducted at
6 months into the intervention in selected clusters
from the intervention and control arms (in the control
arm to understand the implementation process of
existing guidelines by clinicians, ie, usual practice).
The process evaluation aims to describe the health
system and service delivery context in which the inter-
vention was delivered; explore whether or not the
intervention is delivered as intended, both at the
cluster level (training) and the individual level (pro-
vider delivery); and understand mechanisms of impact
both at the provider level and caregiver level. The
methods, which will also be informed by the TDF,36–38
will include document review (eg, meeting minutes),
observation of training sessions and consultations and
qualitative interviews.
In each county we will select one control cluster. After
3 months of implementation we will review prescription
rates in intervention clusters. If all intervention clusters
are performing in a similar way (ie, very good, medium,
poor), then we will select one intervention cluster from
each county. However, if intervention clusters are per-
forming very differently, then we will need to select two
intervention clusters from each county (high and low
performers) to understand cluster level factors. In each
township hospital selected we will interview doctors, the
hospital director, and the pharmacist. We will also
conduct a focus group discussion with caregivers. A sam-
pling frame will be developed and participants will be
purposively selected for inclusion from the selected sites.
Qualitative data will be recorded if the participants
agree to use audio recording. The audio ﬁles will be
transcribed as soon as possible, and any audio ﬁles
recorded by mobile recording devices will be immedi-
ately deleted once they have been transcribed.
Analysis of process evaluation
Qualitative data will be analysed as soon as possible after
it has been collected. The analysis will feed into sub-
sequent interviews and if new issues emerge, these can
be followed up in subsequent interviews. Data will be
audio recorded and transcribed. Nvivo V.10 (QSR
International Pty Ltd) will be used to manage the data.
The data will be analysed using a simple thematic
approach.43 Quality of reporting the qualitative study
will be ensured by adhering to the Consolidated Criteria
for Reporting Qualitative Research (COREQ).44
DISCUSSION
Our study is one of the ﬁrst trials to address irrational
antibiotic prescribing in the primary care context in
China. The study is of great signiﬁcance given the high
levels of antibiotic resistance among children, particu-
larly in developing countries with less stringent anti-
biotic prescribing regulations.6 Our study will contribute
to the currently limited number of studies addressing
irrational antibiotic prescribing in the primary care
context of rural China, and should be made more
widely applicable to similar contexts. In China, most
studies have focused on either clinicians or patients. We,
therefore, aim to test a comprehensive intervention tar-
geting both clinicians and patients, an approach shown
to have the largest effect28 in rural primary care settings.
The evidence-based and user-friendly guideline on
rational antibiotic prescribing is developed to address
the current lack of operational guidelines for primary
care practices. However, simple dissemination of guide-
lines alone has had limited effects on health worker per-
formance,45 46 including in ambulatory care settings.28
Considering the insufﬁcient medical training received
by rural primary care doctors compared to their urban
peers in China,8 we aim to improve their knowledge
through continued professional training in rational anti-
biotic prescribing. Peer review of antibiotics prescribing
is also planned at monthly hospital staff meetings to
monitor ﬁdelity to the intervention, and enhance the
knowledge of doctors. Antibiotics are culturally accepted
in rural China as the ﬁrst response to self-limiting viral
URIs. Thus, educating the caregivers through primary
care doctors is challenging but essential.47 We have
designed an iterative and participatory training process,
with an emphasis on improving the communication and
educational skills of primary care doctors interacting
with elders. Our study will be conducted in poor rural
areas where many caregivers are grandparents as many
of the young generation have temporally migrated to
cities for employment. We have, thus, tailored the educa-
tional materials to be more easily understood by people
with less education. By improving caregivers’ knowledge,
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the intervention is expected to reduce patient demand
for antibiotic prescribing in URIs.
The study ﬁts into the current national priority on anti-
biotics control in China. However, major control efforts
have currently focused on referral hospitals rather than
the primary care level, especially in rural areas. The
study will thus help to shape the policies and regulations
regarding antibiotic use, especially under primary care
settings.12 Multiple interventions have proved effective in
improving the rational use of antibiotics. However, some
interventions, such as point-of-care tests, are not feasible
in primary care settings in poor rural areas of China. In
this trial, all the interventions are embedded within the
routine primary care management and practice. Thus,
additional work and costs that would otherwise have
been added to primary care will be reduced, enhancing
the replicability of the intervention.
Normalisation process theory (NPT)48 49 provides a
useful lens for understanding the processes that affect
the implementation, embedding and integration of
rational antibiotic prescribing into healthcare systems.
However, our main aim for the process evaluation42 is
to understand the barriers and facilitators which are
embedded within the context, the implementation
and mechanisms of impact, and determine which
mechanisms affect behaviour change outcomes. We
also aim to understand how to overcome implementa-
tion challenges and scale up the intervention. For
instance, the uncertain effect of the zero-markup
policy on reducing medicine use may suggest inﬂu-
ences beyond providers and patients such as those of
pharmaceutical companies.
In this study, we use the APR as the outcome rather
than other clinical and laboratory measures, such as the
positive rate of the extended-spectrum β-lactamases, since
we want to focus on provider behaviour; more complex
patient outcomes will be difﬁcult to interpret in the face
of many confounding factors. Trials of reducing anti-
biotic prescriptions for acute respiratory infections are
not uncommon in high-income countries.17 20 24 27
Given that few relevant interventions exist in
low-to-middle income countries, and different studies
have focused on different populations, comparisons
with other studies need to be cautious. Misdiagnosis
(either over-diagnosis or under-diagnosis) of URIs may
happen, which would bias the APR and could even have
a negative impact on treatment. However, this bias will
be minimised as diagnosis and treatment in both arms is
based on Chinese antibiotics use guidelines and IMCI
guidelines.
Outputs will include an operational guideline on the
rational use of antibiotics for URIs among children, and
training modules and other materials that may be scaled
up in Guangxi and other western provinces. These mate-
rials also have the potential to be adapted to other low-
income and middle-income country contexts. We, there-
fore, believe that this trial will greatly contribute to
improving the prescribing behaviour of doctors in the
rural primary care context in China, and other develop-
ing countries.
Ethics and dissemination
The results will be disseminated through policy briefs,
workshops, peer-reviewed publications, and local and
international conferences.
There have been no modiﬁcations to the protocol
which may impact on the conduct of the study, potential
beneﬁt and safety of the patients, including changes in
the objectives, design, population, sample sizes, proce-
dures or signiﬁcant administrative aspects of the study.
Any amendment in the future will seek prior approval
from the Ethics Committees.
No consent form will be provided for prescription
review. Guangxi CDC will seek agreement from each
hospital under study. It will be pointed out that we will
use the patients’ information only for research purposes,
and thus ensure the conﬁdentiality of the patients.
Personal identifying information, such as names and
national ID, would be deleted before data is inputed
into our research ﬁles. Each prescription will be
assigned a unique study identiﬁcation number. For the
provider interviews, we will permit verbal consent to be
given by providers, if requested, for interviews so as to
protect people working in bureaucratic health systems,
and to obtain as much objective information as much.
Regarding the patient/caregiver focus groups, written
informed consent will be obtained from each participant
(verbal consent from the illiterate parents/caregivers).
Information sheets will be provided and/or explained
for both providers (see online supplementary info 2)
and caregivers (see online supplementary info 3).
Physical hard copies of study data materials will be
stored securely in a locked cabinet, separate from the
data of other studies. The photographed prescriptions
will be deleted as soon as possible following information
extraction. For the qualitative data, only the researchers
conducting the study will know the names of partici-
pants, and have access to the responses from individual
participants.
Only the principal investigators (XW and ML) will be
given access to the cleaned data sets. Project data sets
will be stored electronically by the China Global Health
Research and Development, and all data sets will be
password protected.
We will disseminate the main ﬁndings to provincial
and national CDC and authorities, our Communicable
Disease—Health Service Delivery (COMDIS-HSD)
Research Programme Consortium country partners in
South Asia and Africa, and relevant international stake-
holders. We will publish the ﬁndings in national and
international journals, and present these at national and
international conferences.
The protocol adheres to the recommendations pro-
vided by the SPIRIT 2013.50 All items from the WHO
Trial Registration Data Set are available in online supple-
mentary info 4.
8 Zou G, et al. BMJ Open 2016;6:e010544. doi:10.1136/bmjopen-2015-010544
Open Access
 o
n
 9 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2015-010544 on 27 May 2016. Downloaded from 
Author affiliations
1China Global Health Research and Development, Shenzhen, China
2Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario,
Canada
3Nuffield Centre for International Health and Development, University of
Leeds, Leeds, UK
4School of Public Health and Primary Care, Chinese University of Hong Kong,
Hong Kong, China
5Guangxi Autonomous Region Centre for Disease Control and Prevention,
Nanning, China
6Centre for Health Management and Policy, Shandong University, Jinan, China
Contributors GZ and XW drafted the manuscript. JW, ML, JZ, YHH, YYH, ZZ,
SD, RK, HE, QS contributed to designing the trial and participated in the pilot
study. JPH contributed to the statistical issues in the study design, and wrote
the statistical analysis plan. RK contributed to the design of the process
evaluation and qualitative methods. HE contributed to trial and process
evaluation design, and critically reviewed the manuscript. CB, SD and GZ
contributed to ethics development. CB, JW and JPH critically reviewed the
manuscript. XW and ML are co-principal investigators of the trial. All authors
made substantive contributions to the trial development and provided final
approval for this manuscript.
Funding The trial is supported by the Department for International
Development of the UK Government (DFID) via the COMDIS-HSD Research
Programme Consortium. The Development Grant of Joint Global Health Trial
supported by DFID, Wellcome Trust and Medical Research Council (MRC MR/
M022161/1), has contributed to the pilot study. The funding sources had no
role in the design of this study and will not have any role during its execution,
analyses, data interpretation, or decision to submit results.
Competing interests None declared.
Patient consent Obtained.
Ethics approval Ethics Committees of Guangxi Provincial Centre for Disease
Control and Prevention, China and University of Leeds School of Medicine.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. WHO. Promoting Rational Use of Medicines: Core Components -
WHO Policy Perspectives on Medicines, No. 005, September 2002.
Geneva: World Health Organization, 2002. http://apps.who.int/
medicinedocs/en/d/Jh3011e/
2. WHO. Medicines use in primary care in developing and transitional
countries: Fact book summarizing results from studies reported
between 1990 and 2006. 2009. Geneva: World Health Organization.
http://www.who.int/medicines/publications/primary_care_8April09.pdf
3. Sabaté E. Adherence to long-term therapies. Evidence for action.
World Health Organization, 2003.
4. Alves Galvao MG, Rocha Crispino Santos MA, Alves da Cunha AJ.
Antibiotics for preventing suppurative complications from
undifferentiated acute respiratory infections in children under five
years of age. Cochrane Database Syst Rev 2014;(2):Cd007880.
5. Andrews T, Thompson M, Buckley DI, et al. Interventions to
influence consulting and antibiotic use for acute respiratory tract
infections in children: a systematic review and meta-analysis. PLoS
ONE 2012;7:e30334.
6. Ilic K, Jakovljevic E, Skodric-Trifunovic V. Social-economic factors
and irrational antibiotic use as reasons for antibiotic resistance of
bacteria causing common childhood infections in primary healthcare.
Eur J Pediatr 2012;171:767–77.
7. Li Y. China’s misuse of antibiotics should be curbed. BMJ 2014;348:
g1083.
8. Anand S, Fan VY, Zhang J, et al. China’s human resources for
health: quantity, quality, and distribution. Lancet 2008;372:1774–81.
9. Gu J, Zhao J, Huang Y, et al. Use of antibiotics by urban and rural
residents in Heilongjiang Province, China: cross-sectional study.
Trop Med Int Health 2015;20:1815–182211.
10. Wang J, Wang P, Wang X, et al. Use and prescription of antibiotics
in primary health care settings in China. JAMA Intern Med
2014;174:1914–20.
11. Dong L, Yan H, Wang D. Antibiotic prescribing patterns in village
health clinics across 10 provinces of Western China. J Antimicrob
Chemother 2008;62:410–15.
12. Xiao Y, Li L. Legislation of clinical antibiotic use in China. Lancet
Infect Dis 2013;13:189–91.
13. Mao W, Vu H, Xie Z, et al. Systematic review on irrational use
of medicines in China and Vietnam. PLoS ONE 2015;10:
e0117710.
14. Harbarth S, Albrich W, Brun-Buisson C. Outpatient antibiotic use
and prevalence of antibiotic-resistant pneumococci in France and
Germany: a sociocultural perspective. Emerging Infect Dis
2002;8:1460–7.
15. Mainous AG III, Lambourne CA, Nietert PJ. Impact of a clinical
decision support system on antibiotic prescribing for acute
respiratory infections in primary care: quasi-experimental trial. J Am
Med Inform Assoc 2013;20:317–24.
16. Litvin CB, Ornstein SM, Wessell AM, et al. Use of an electronic
health record clinical decision support tool to improve antibiotic
prescribing for acute respiratory infections: the ABX-TRIP study.
J Gen Intern Med 2013;28:810–16.
17. Gonzales R, Anderer T, McCulloch CE, et al. A cluster randomized
trial of decision support strategies for reducing antibiotic use in acute
bronchitis. JAMA Intern Med 2013;173:267–73.
18. Litvin CB, Ornstein SM, Wessell AM, et al. Adoption of a clinical
decision support system to promote judicious use of antibiotics for
acute respiratory infections in primary care. Int J Med Inform
2012;81:521–6.
19. Hingorani R, Mahmood M, Alweis R. Improving antibiotic adherence
in treatment of acute upper respiratory infections: a quality
improvement process. J Community Hosp Intern Med Perspect
2015;5:27472.
20. Little P, Stuart B, Francis N, et al. Effects of internet-based training
on antibiotic prescribing rates for acute respiratory-tract infections:
a multinational, cluster, randomised, factorial, controlled trial. Lancet
2013;382:1175–82.
21. Cals JW, de Bock L, Beckers PJ, et al. Enhanced communication
skills and C-reactive protein point-of-care testing for respiratory tract
infection: 3.5-year follow-up of a cluster randomized trial. Ann Fam
Med 2013;11:157–64.
22. Altiner A, Berner R, Diener A, et al. Converting habits of antibiotic
prescribing for respiratory tract infections in German primary care—
the cluster-randomized controlled CHANGE-2 trial. BMC Fam Pract
2012;13:124.
23. Price EL, Mackenzie TD, Metlay JP, et al. A computerized education
module improves patient knowledge and attitudes about appropriate
antibiotic use for acute respiratory tract infections. Patient Educ
Couns 2011;85:493–8.
24. Pettersson E, Vernby A, Molstad S, et al. Can a multifaceted
educational intervention targeting both nurses and physicians
change the prescribing of antibiotics to nursing home residents?
A cluster randomized controlled trial. J Antimicrob Chemother
2011;66:2659–66.
25. Ruvinsky S, Monaco A, Perez G, et al. Effectiveness of a program
to improve antibiotic use in children hospitalized in a children’s
tertiary care facility in Argentina. Arch Argent Pediatr 2014;112:
124–31.
26. Liang X, Xia T, Zhang X, et al. Governance structure reform and
antibiotics prescription in community health centres in Shenzhen,
China. Fam Pract 2014;31:311–18.
27. Persell SD, Friedberg MW, Meeker D, et al. Use of behavioral
economics and social psychology to improve treatment of acute
respiratory infections (BEARI): rationale and design of a cluster
randomized controlled trial [1RC4AG039115-01]—study protocol
and baseline practice and provider characteristics. BMC Infect Dis
2013;13:290.
28. Arnold Sandra R, Straus Sharon E. Interventions to improve
antibiotic prescribing practices in ambulatory care. Cochrane
Database Syst Rev 2005;(4):CD003539.
29. Huang SS, Rifas-Shiman SL, Kleinman K, et al. Parental knowledge
about antibiotic use: results of a cluster-randomized, multicommunity
intervention. Pediatrics 2007;119:698–706.
30. Taylor JA, Kwan-Gett TS, McMahon EM Jr. Effectiveness of a
parental educational intervention in reducing antibiotic use in
children: a randomized controlled trial. Pediatr Infect Dis J
2005;24:489–93.
Zou G, et al. BMJ Open 2016;6:e010544. doi:10.1136/bmjopen-2015-010544 9
Open Access
 o
n
 9 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2015-010544 on 27 May 2016. Downloaded from 
31. Wheeler JG, Fair M, Simpson PM, et al. Impact of a waiting room
videotape message on parent attitudes toward pediatric antibiotic
use. Pediatrics 2001;108:591–6.
32. Yang L, Liu C, Wang L, et al. Public reporting improves antibiotic
prescribing for upper respiratory tract infections in primary care:
a matched-pair cluster-randomized trial in China. Health Res Policy
Syst 2014;12:61.
33. Hansson L, Hedner T, Dahlf B. Prospective Randomized Open
Blinded End-point (PROBE) Study: a novel design for intervention
trials. Blood Press 1992;1:113–19.
34. Medical Research Council. Medical Research Council (MRC)
framework Developing and evaluating complex interventions: new
guidance. http://wwwmrcacuk/documents/pdf/complex-interventions-
guidance/
35. Hu Y, Walley J, Chou R, et al. Interventions to reduce childhood
antibiotic prescribing for upper respiratory infections: systematic
review and meta-analysis. J Epidemiol Community Health. In press.
36. Cane J, O’Connor D, Michie S. Validation of the theoretical domains
framework for use in behaviour change and implementation
research. Implement Sci 2012;7:37.
37. French SD, Green SE, O’Connor DA, et al. Developing
theory-informed behaviour change interventions to implement
evidence into practice: a systematic approach using the Theoretical
Domains Framework. Implement Sci 2012;7:38.
38. Tavender EJ, Bosch M, Gruen RL, et al. Understanding practice: the
factors that influence management of mild traumatic brain injury in
the emergency department-a qualitative study using the Theoretical
Domains Framework. Implement Sci 2014;9:8.
39. Michie S, Johnston M, Francis J, et al. From theory to intervention:
mapping theoretically derived behavioural determinants to behaviour
change techniques. Appl Psychol 2008;57:660–80.
40. Chan ED, Strand MJ, Iseman MD. Multidrug-resistant tuberculosis
(TB) resistant to fluoroquinolones and streptomycin but susceptible to
second-line injection therapy has a better prognosis than extensively
drug-resistant TB. Clin Infect Dis 2009;48:e50–2.
41. Hayes RJ, Moulton LH. Cluster randomised trials. CRC Press, 2009.
42. Moore GF, Audrey S, Barker M, et al. Process evaluation of complex
interventions: Medical Research Council guidance. BMJ 2015;350:
h1258.
43. Patton M. Qualitative research and evaluation methods: integrating
theory and practice. 4th edn: SAGE, 2015.
44. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting
qualitative research (COREQ): a 32-item checklist for interviews and
focus groups. Int J Qual Health Care 2007;19:349.
45. Giguere A, Legare F, Grimshaw J, et al. Printed educational
materials: effects on professional practice and healthcare outcomes.
Cochrane Database Syst Rev 2012;(10):Cd004398.
46. Rowe AK, de Savigny D, Lanata CF, et al. How can we achieve and
maintain high-quality performance of health workers in low-resource
settings? Lancet 2005;366:1026–35.
47. Yu M, Zhao G, Stalsby Lundborg C, et al. Knowledge, attitudes, and
practices of parents in rural China on the use of antibiotics in
children: a cross-sectional study. BMC Infect Dis 2014;14:112.
48. Finch TL, Rapley T, Girling M, et al. Improving the normalization of
complex interventions: measure development based on normalization
process theory (NoMAD): study protocol. Implement Sci 2013;8:43.
49. McEvoy R, Ballini L, Maltoni S, et al. A qualitative systematic review
of studies using the normalization process theory to research
implementation processes. Implement Sci 2014;9:2.
50. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation
and elaboration: guidance for protocols of clinical trials. BMJ
2013;346:e7586.
10 Zou G, et al. BMJ Open 2016;6:e010544. doi:10.1136/bmjopen-2015-010544
Open Access
 o
n
 9 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2015-010544 on 27 May 2016. Downloaded from 
